ANZCTR search results

RATIONALE: Steroid therapy, such as dexamethasone, may reduce swelling, pain, and other symptoms of inflammation and may be effective in treating some of the problems caused by cancer and cancer treatment. Supportive care improves the quality of life of patients with a serious or life-threatening disease, and prevents or treats symptoms of cancer, side effects of treatment, and other problems related to cancer or its treatment. Radiation therapy uses high-energy x-rays to kill tumor cells. It is not yet known whether dexamethasone given together with supportive care is more effective with or without whole-brain radiation therapy in treating patients with brain metastases. PURPOSE: This randomized phase III trial is studying dexamethasone and supportive care to see how well it works with or without whole-brain radiation therapy in improving the quality of life of patients with non-small cell lung cancer that has spread to the brain and cannot be removed by surgery.

The use of androgen deprivation therapy (ADT) to reduce testosterone levels in men with prostate carcinoma is accompanied by a number of adverse side effects. This study will investigate the effects of aerobic and resistance exercise on reversing musculoskeletal and cardiorespiratory related side effects in prostate cancer patients undertaking ADT.

This is a phase II randomised, single, dose, masked, multicentre trial to determine the efficacy of 0.5mg Ranibizumab intravitreal injections in the treatment of macular oedema secondary to BRVO over one year compared with standard laser grid. Patients eligible for the study will be randomised to receive an intravitreal injection of 0.5mg Ranibizumab or placebo for 6 months. Patients will be monitored for a further 6 months to see whether further treatment is required. Patients are evaluated by a masked investigator at 3 and 6 months to determine whether they require laser grid, the current standard treatment for this condition. The primary outcome will be the proportion of eyes showing an improvement of visual acuity by 10 letters on the LogMar chart for the treatment group versus the sham group at 52 weeks compared with baseline. The secondary outcome will be the change in baseline OCT central macular thickness between the treatment and the sham groups at 52 weeks. The tertiary objective will be the change in the mean capillary non-perfusion between the sham/laser and treatment groups at 52 weeks and the number of patients requiring grid macular laser.

The purpose of this study is to determine if there is a difference between the number and severity of phototoxic reactions that occurr in patients with Erythropoietic Protoporphyria (EPP) treated with CUV1647 and placebo.

This study will evaluate the safety, including blood sampling for pharmacokinetic monitoring, of a new topical anti-infective (NEO101) applied to each nostril. A single dose will be applied on Day 1 and Day 7 of the study, and three-times-daily doses will be applied on Days 4, 5 and 6.

Trial will involve 80 obese subjects with BMI above 30. It will be randomised placebo controlled trial. Subjects will take Chinese herbal capsules for 12 weeks. The endpoints will be evaluated every 2 weeks.

Main purpose of this study is to identify if there is a need to offer of a large print label, on eye medications, to glaucoma patients that display certain visual function and disease characteristics. In turn, this may assist these patients in adhering to their prescribed treatment.

Gout is an inflammatory condition caused by the deposition of urate crystals in tissues/joints. Allopurinol is a common and effective treatment to prevent gout. Probenecid, although less common used, is also effective, but may be less effective in patients with impaired renal function. In patients with tophaceous gout or those unresponsive to allopurinol/probenecid alone, the combination is sometimes prescribed. Studies in healthy subjects have shown that although the elimination of oxypurinol (active metabolite of allopurinol) is increased when probenecid is taken concurrently with allopurinol, the combination therapy has a greater therapeutic effect (decreased plasma urate concentrations). The relevance of these findings for gouty patients is unknown. Thus, this project will examine the interaction between allopurinol and probenecid in gouty patients and determine the therapeutic effect in patients with a range of renal function.

Aims - To refine treatment selection for women with non-low risk DCIS to optimise disease control & minimise toxicity - Clinical: To evaluate outcomes after breast conserving surgery by investigating two factors - Addition of tumour bed boost to whole breast RT - Dose fractionation - QoL To compare QoL, psychological distress, perceived risk of invasive disease & perceived cosmetic outcomes amongst treatment arms - Biological: To identify biomarkers/molecular signatures of DCIS predictive of invasive recurrence for therapy individualisation

Obstructive sleep apnoea (OSA) is a relatively common condition in children with a peak incidence between 2-6 years, coincident with the maximal size of adenotonsillar tissue relative to the upper airway. OSA has effects on neurocognition and behaviour which may be reversed by adenotonsillectomy. However, surgical treatment carries risks which are increased in children with OSA and children under the age of 3 years. Recent studies have suggested that anti-inflammatory treatment with nasal corticosteroids or with anti-leukotriene agents may be an alternative to surgery. Montelukast is an anti-leukotriene receptor antagonist with minimal risk of adverse effects. A randomised double-blind placebo-controlled trial of montelukast for the treatment of OSA related to adenotonsillar hypertrophy in children is proposed. Following a sleep study (PSG) showing mild OSA, children will be randomised to a once daily dose of Montelukast or placebo for 8 weeks. At the end of treatment a repeat sleep study will be performed as well as measures of disease-specific quality of life, behaviour, attention and cognition.